Option Care Health, Inc. (OPCH)
NEUTRALFundamental
72
Kurs
$23.36
Marktkapitalisierung
$3.58B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$5.67B
Letzte 12 Monate (bis 31.3.2026)
Nettogewinn
$206M
Letzte 12 Monate (bis 31.3.2026)
Freier Cashflow
$217M
Gesamtes Eigenkapital
$1.33B
Gesamtverbindlichkeiten
$2.13B
Current Ratio
1.64
Zinsdeckungsgrad
6.06
Schulden/EBITDA
3.13
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$30.30
Aktueller Kurs
$23.36
Sicherheitsmarge
+22.9%
Innerer-Wert-Spanne
$19.70 - $40.91
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
18.49
ROE
15.7%
P/B-Verhältnis
2.75
P/FCF
17.49
Bruttomarge
19.2%
ROIC
9.9%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
9.9%
WACC
6.8%
ROIC − WACC
+3.1 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamentalanalyse-Kriterien
Bestanden (20)
- EPS shows upward trend
- EPS CAGR 15.84%
- Price CAGR 19.01%
- ROIC 9.9%
- P/FCF 17.49
- P/B Ratio 2.75
- Debt/Equity ratio
- Operating Margin 5.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.8%
- Revenue Growth 5Y 13.3%
- Analyst Consensus 68% Buy
- Earnings Quality (OCF/NI) 1.23
- Share Dilution -5.1%
- Piotroski F-Score 5/9
Nicht bestanden (6)
- Gross Margin 19.2%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 2.4%
- Net Margin Trend 3.6% vs 4.1%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. John Charles Rademacher | CEO, President & Director | 58 |
| Mr. Luke Whitworth | Chief Operating Officer | 44 |
| Mr. Collin G. Smyser | General Counsel & Corporate Secretary | 46 |
| Ms. Nicole Maggio | Senior VP, Controller & Principal Accounting Officer | 42 |
| Mr. Brett Michalak | Chief Technology Officer | - |
| Ms. Alyssa Moy | Chief Information Officer | - |
| Ms. Stacey Mahone | Senior VP & Chief Compliance Officer | - |
| Mr. Jorge Ramirez | Senior VP of Strategy and Corporate Development | - |
| Mr. Michael Bavaro | Chief Human Resources & Chief Diversity Officer | 47 |
| Ms. Julie Koenig | Senior Vice President of Operations | - |
Prüfungsrisiko
1
Vorstandsrisiko
2
Vergütungsrisiko
4
Aktionärsrechterisiko
5
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for OPCH, sourced from Markets Gazette.
- 2/24/2026NEUTRALOption Care (OPCH) Earnings Call Transcript
Investors in Option Care Health (OPCH) are awaiting the release of the earnings call transcript, scheduled for February 24, 2026. While the specific content is not yet available, this event is crucial for understanding the company's financial performance and future outlook. Earnings calls provide detailed insights into revenues, profits, margins, and guidance, which are fundamental elements for assessing a company's operational and strategic health. The analysis of this data will enable analysts and shareholders to make informed judgments about the stock's short- to medium-term trajectory. The current lack of content implies a waiting period for the market, which will react once the information is made public.
via Markets Gazette